|
|
Legal status
Patent not validated
| (51) | INT.CL. | C07D 471/04 | |
| A61K 31/437 | |||
| A61K 31/444 | |||
| A61P 35/00 |
| (11) | Number of the document | 3461823 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17812632.2 |
| Date of filing the European patent application | 2017-06-09 | |
| (97) | Date of publication of the European application | 2019-04-03 |
| (45) | Date of publication and mention of the grant of the patent | 2020-06-03 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/CN2017/087711 |
| Date | 2017-06-09 |
| (87) | Number | WO 2017/215521 |
| Date | 2017-12-21 |
| (30) | Number | Date | Country code |
| 201610430773 | 2016-06-17 | CN |
| (72) |
CHEN, Minhua, CN
ZHANG, Yanfeng, CN
ZOU, Po, CN
ZHANG, Xiaoyu, CN
|
| (73) |
Crystal Pharmaceutical (Suzhou) Co., Ltd.,
B4-301 Biobay 218 Xinghu Street Suzhou Industrial Park, Suzhou, Jiangsu 215123,
CN
|
| (54) | PEXIDARTINIB HYDROCHLORIDE CRYSTAL FORMS, PREPARATION METHOD THEREFOR AND USE THEREOF |
| PEXIDARTINIB HYDROCHLORIDE CRYSTAL FORMS, PREPARATION METHOD THEREFOR AND USE THEREOF |